What Changed — Core Amendments
Rule 52 — Prior Intimation Pathway
Online Prior Intimation replaces formal CLA permission for low-risk manufacturing activities. Immediate acknowledgment = right to proceed. Eligible: analytical testing, non-clinical testing (most categories), BA/BE studies (approved drugs), API non-clinical work, formulation/API manufacturing via CT-12/CT-13.
Rules 53 & 60 — Timeline Halved
Review timeline cut from 90 working days to 45 working days uniformly across all sub-rules for new drug/IND test licence (Rule 53) and API test licence (Rule 60).
Rules 58 & 62 — Fully Substituted
Suspension/cancellation rules now cover both permission holders AND PI acknowledgment holders. Rule 58 (IND): 60-day appeal window. Rule 62 (API/Formulation): 45-day appeal window. CLA must give show-cause + opportunity to be heard before acting.
Rule 66 — Labelling Updated
Sub-rule (2) substituted: containers for drugs manufactured on behalf of another must now show manufacturer name/address, recipient name/address, scientific name or reference identifier, and manufacturing purpose.
Categories Always Requiring Full CLA Permission
These 6 high-risk categories are excluded from Prior Intimation — full permission still required:
Sex Hormones · Cytotoxic Drugs · β-Lactam Antibiotics · Biologics with Live Organisms · Narcotics · Psychotropic Drugs
Sex Hormones · Cytotoxic Drugs · β-Lactam Antibiotics · Biologics with Live Organisms · Narcotics · Psychotropic Drugs
NDCT 2019 vs 2026 — Direct Comparison
| Parameter | NDCT Rules 2019 | NDCT Amendment 2026 |
|---|---|---|
| Non-clinical manufacturing | Formal CLA permission required | Online Prior Intimation — immediate acknowledgment |
| BA/BE study initiation | Prior CDSCO approval mandatory | Prior Intimation route for approved drugs in ICH jurisdictions |
| Review timeline (Rules 53/60) | 90 working days | 45 working days — 50% reduction |
| Forms CT-10/CT-12/CT-13 | Permission application only | Dual-mode: Permission OR Prior Intimation |
| Rule 58/62 enforcement | Permission-only suspension/cancellation | Covers both permission AND PI acknowledgment; dual appeal modes |
| Labelling — Rule 66(2) | Manufacturer details only | Adds recipient, scientific name, manufacturing purpose |
| Digital infrastructure | SUGAM portal (existing) | NSWS + SUGAM + dedicated PI modules + CDSCO circular (Mar 2026) |
| Appeal period | 60 days (all) | 60 days (IND/Rule 58) · 45 days (API/Rule 62) |
| Regulatory philosophy | Control-first pre-approval model | Risk-proportionate trust-based governance (Jan Vishwas Siddhant) |
Sectoral Impact
CROs & Sponsors
- BA/BE initiation no longer gated by CDSCO approval
- 90-day gain per study (CDSCO estimate)
- Faster Phase I/IND material preparation
- More competitive with Western regulatory timelines
- Reduced carrying costs per project
Generic Pharma
- ~4,500 BA/BE studies per year now directly impacted
- Compliance burden reduced — paper-in-person inspection replaced by digital oversight
- Need to maintain robust pre-approval to process-based model
- SUGAM digital compliance required; excluded drugs still need full permission
API Manufacturers
- CT-13 PI route available for non-clinical API work
- GMP compliance mandatory for all clinical-stage APIs
- Destruction of clinical-stage APIs must be documented and acknowledged
- PI acknowledgment disposal requires formal permission
Clinical Trial Sites
- Faster IND material availability — earlier trial start
- Ethics Committee (EC) feasibility — reinforced upstream
- 50% faster test licence timelines (Rules 53/60)
- DSRC/CDSCO Sponsor oversight — investigators enrolled equally under PI route
- Sites must maintain audit-ready documentation
Digital Regulatory Infrastructure
SUGAM Portal
Primary submission platform for all CT forms. CT-10, CT-12, CT-13 now support Prior Intimation mode. Electronic acknowledgment generated instantly on submission — no manual follow-up required.
NSWS Integration
National Single Window System enables unified digital filing across ministries. Reduces multi-portal complexity for large pharma sponsors and CROs operating across jurisdictions.
Audit Trail System
Digital filings create immutable compliance records. Retrospective audits supported under the trust-based governance model. Data integrity requirements apply throughout the PI lifecycle.
CDSCO Circular — 6 March 2026
Implementation circular defines PI workflow in operational detail. Issued the day before rules came into force. Helpdesk: helpdesk.sugam@cdsco.nic.in | +91-11-23502918
Policy Context & Significance
Jan Vishwas Siddhant
Trust-based regulatory philosophy underlying the 2026 reforms. Reduces presumptive requirements on lower-risk actors while maintaining rigorous oversight where genuinely warranted.
Ease of Doing Business
Explicit Ministry framing. India competing on regulatory speed, not just cost. Signals durable policy direction rather than one-off concession.
Regulatory Lineage
NDCT Rules 2019 (G.S.R. 227E) → Last amended G.S.R. 581(E) Sep 2024 → Draft G.S.R. 588(E) Aug 2025 → Final G.S.R. 46(E) Jan 2026 → In force Mar 2026.
Second Amendment — BA/BE
Extends Prior Intimation directly to BA/BE studies. A company may now initiate a BA/BE study by filing an online intimation to CDSCO, without waiting for prior approval. The acknowledgment alone is sufficient to proceed.